25 XP   0   0   10

Impedimed Ltd
Buy, Hold or Sell?

Let's analyse Impedimed together

PenkeI guess you are interested in Impedimed Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Impedimed Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Impedimed Ltd

I send you an email if I find something interesting about Impedimed Ltd.

Quick analysis of Impedimed (30 sec.)










What can you expect buying and holding a share of Impedimed? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
A$0.03
Expected worth in 1 year
A$0.05
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$0.02
Return On Investment
23.6%

For what price can you sell your share?

Current Price per Share
A$0.09
Expected price per share
A$0.061 - A$0.091
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Impedimed (5 min.)




Live pricePrice per Share (EOD)

A$0.09

Intrinsic Value Per Share

A$-0.11 - A$-0.08

Total Value Per Share

A$-0.08 - A$-0.05

2. Growth of Impedimed (5 min.)




Is Impedimed growing?

Current yearPrevious yearGrowGrow %
How rich?$39.9m$33.5m$6.4m16.2%

How much money is Impedimed making?

Current yearPrevious yearGrowGrow %
Making money-$13.4m-$13m-$424.6k-3.2%
Net Profit Margin-182.4%-189.4%--

How much money comes from the company's main activities?

3. Financial Health of Impedimed (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#186 / 345

Most Revenue
#208 / 345

Most Profit
#283 / 345

Most Efficient
#271 / 345
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Impedimed? (5 min.)

Welcome investor! Impedimed's management wants to use your money to grow the business. In return you get a share of Impedimed.

What can you expect buying and holding a share of Impedimed?

First you should know what it really means to hold a share of Impedimed. And how you can make/lose money.

Speculation

The Price per Share of Impedimed is A$0.086. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Impedimed.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Impedimed, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.03. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Impedimed.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-7.7%-0.01-7.7%-0.01-7.5%-0.01-8.0%-0.01-7.9%
Usd Book Value Change Per Share0.003.7%0.003.7%0.019.6%0.001.9%0.001.9%
Usd Dividend Per Share0.000.2%0.000.2%0.000.1%0.000.1%0.000.1%
Usd Total Gains Per Share0.003.9%0.003.9%0.019.8%0.002.0%0.002.0%
Usd Price Per Share0.12-0.12-0.04-0.07-0.23-
Price to Earnings Ratio-17.75--17.75--6.21--9.86--35.69-
Price-to-Total Gains Ratio35.50-35.50-4.76--25.59-1.64-
Price to Book Ratio5.98-5.98-2.42-7.07-17.64-
Price-to-Total Gains Ratio35.50-35.50-4.76--25.59-1.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0564418
Number of shares17717
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (17717 shares)58.9630.65
Gains per Year (17717 shares)235.85122.61
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1102262268114113
22045246216229236
32967869825343359
43990493433457482
5491130117041572605
6591356140649686728
7681583164258801851
8781809187866915974
988203521147410291097
1098226123508211441220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.016.02.00.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%6.04.00.060.0%8.010.00.044.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.01.080.0%4.00.06.040.0%4.00.014.022.2%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%6.04.00.060.0%8.010.00.044.4%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Impedimed

About Impedimed Ltd

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Fundamental data was last updated by Penke on 2024-02-17 12:39:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Impedimed Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Impedimed earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Impedimed to the Medical Devices industry mean.
  • A Net Profit Margin of -182.4% means that $-1.82 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Impedimed Ltd:

  • The MRQ is -182.4%. The company is making a huge loss. -2
  • The TTM is -182.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-182.4%TTM-182.4%0.0%
TTM-182.4%YOY-189.4%+6.9%
TTM-182.4%5Y-316.1%+133.7%
5Y-316.1%10Y-360.5%+44.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-182.4%-11.2%-171.2%
TTM-182.4%-16.4%-166.0%
YOY-189.4%-13.2%-176.2%
5Y-316.1%-18.9%-297.2%
10Y-360.5%-22.4%-338.1%
1.1.2. Return on Assets

Shows how efficient Impedimed is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Impedimed to the Medical Devices industry mean.
  • -29.9% Return on Assets means that Impedimed generated $-0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Impedimed Ltd:

  • The MRQ is -29.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -29.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-29.9%TTM-29.9%0.0%
TTM-29.9%YOY-33.9%+4.0%
TTM-29.9%5Y-59.0%+29.2%
5Y-59.0%10Y-52.4%-6.6%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.9%-3.5%-26.4%
TTM-29.9%-4.4%-25.5%
YOY-33.9%-3.5%-30.4%
5Y-59.0%-3.8%-55.2%
10Y-52.4%-4.3%-48.1%
1.1.3. Return on Equity

Shows how efficient Impedimed is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Impedimed to the Medical Devices industry mean.
  • -33.7% Return on Equity means Impedimed generated $-0.34 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Impedimed Ltd:

  • The MRQ is -33.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -33.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-33.7%TTM-33.7%0.0%
TTM-33.7%YOY-38.9%+5.2%
TTM-33.7%5Y-76.8%+43.1%
5Y-76.8%10Y-63.8%-13.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-33.7%-3.8%-29.9%
TTM-33.7%-5.0%-28.7%
YOY-38.9%-4.2%-34.7%
5Y-76.8%-5.4%-71.4%
10Y-63.8%-6.1%-57.7%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Impedimed Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Impedimed is operating .

  • Measures how much profit Impedimed makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Impedimed to the Medical Devices industry mean.
  • An Operating Margin of -204.4% means the company generated $-2.04  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Impedimed Ltd:

  • The MRQ is -204.4%. The company is operating very inefficient. -2
  • The TTM is -204.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-204.4%TTM-204.4%0.0%
TTM-204.4%YOY-205.2%+0.8%
TTM-204.4%5Y-358.8%+154.4%
5Y-358.8%10Y-382.9%+24.1%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ-204.4%-32.8%-171.6%
TTM-204.4%-13.8%-190.6%
YOY-205.2%-11.4%-193.8%
5Y-358.8%-19.5%-339.3%
10Y-382.9%-24.8%-358.1%
1.2.2. Operating Ratio

Measures how efficient Impedimed is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 3.04 means that the operating costs are $3.04 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Impedimed Ltd:

  • The MRQ is 3.044. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.044. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.044TTM3.0440.000
TTM3.044YOY3.052-0.008
TTM3.0445Y4.588-1.544
5Y4.58810Y4.958-0.370
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0441.454+1.590
TTM3.0441.467+1.577
YOY3.0521.446+1.606
5Y4.5881.468+3.120
10Y4.9581.379+3.579
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Impedimed Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Impedimed is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 8.88 means the company has $8.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Impedimed Ltd:

  • The MRQ is 8.884. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.884. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.884TTM8.8840.000
TTM8.884YOY6.443+2.441
TTM8.8845Y5.202+3.682
5Y5.20210Y8.207-3.005
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8842.888+5.996
TTM8.8842.861+6.023
YOY6.4433.742+2.701
5Y5.2023.647+1.555
10Y8.2073.546+4.661
1.3.2. Quick Ratio

Measures if Impedimed is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Impedimed to the Medical Devices industry mean.
  • A Quick Ratio of 8.48 means the company can pay off $8.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Impedimed Ltd:

  • The MRQ is 8.476. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.476. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.476TTM8.4760.000
TTM8.476YOY6.096+2.381
TTM8.4765Y4.850+3.626
5Y4.85010Y7.735-2.885
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4761.630+6.846
TTM8.4761.644+6.832
YOY6.0962.218+3.878
5Y4.8502.275+2.575
10Y7.7352.259+5.476
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Impedimed Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Impedimed assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Impedimed to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.11 means that Impedimed assets are financed with 11.4% credit (debt) and the remaining percentage (100% - 11.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Impedimed Ltd:

  • The MRQ is 0.114. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.114. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.114TTM0.1140.000
TTM0.114YOY0.130-0.016
TTM0.1145Y0.194-0.080
5Y0.19410Y0.143+0.051
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1140.377-0.263
TTM0.1140.383-0.269
YOY0.1300.329-0.199
5Y0.1940.442-0.248
10Y0.1430.464-0.321
1.4.2. Debt to Equity Ratio

Measures if Impedimed is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Impedimed to the Medical Devices industry mean.
  • A Debt to Equity ratio of 12.9% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Impedimed Ltd:

  • The MRQ is 0.129. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.129. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.129TTM0.1290.000
TTM0.129YOY0.150-0.021
TTM0.1295Y0.252-0.123
5Y0.25210Y0.177+0.075
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1290.527-0.398
TTM0.1290.548-0.419
YOY0.1500.464-0.314
5Y0.2520.615-0.363
10Y0.1770.699-0.522
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Impedimed Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Impedimed generates.

  • Above 15 is considered overpriced but always compare Impedimed to the Medical Devices industry mean.
  • A PE ratio of -17.75 means the investor is paying $-17.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Impedimed Ltd:

  • The EOD is -8.479. Based on the earnings, the company is expensive. -2
  • The MRQ is -17.747. Based on the earnings, the company is expensive. -2
  • The TTM is -17.747. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.479MRQ-17.747+9.268
MRQ-17.747TTM-17.7470.000
TTM-17.747YOY-6.210-11.537
TTM-17.7475Y-9.857-7.890
5Y-9.85710Y-35.691+25.833
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-8.479-1.171-7.308
MRQ-17.747-1.550-16.197
TTM-17.747-2.256-15.491
YOY-6.210-2.560-3.650
5Y-9.857-2.034-7.823
10Y-35.691-1.821-33.870
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Impedimed Ltd:

  • The EOD is -7.223. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.117. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.117. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.223MRQ-15.117+7.894
MRQ-15.117TTM-15.1170.000
TTM-15.117YOY-5.910-9.207
TTM-15.1175Y-10.118-4.999
5Y-10.11810Y-42.292+32.174
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-7.223-1.826-5.397
MRQ-15.117-2.390-12.727
TTM-15.117-4.038-11.079
YOY-5.910-5.910+0.000
5Y-10.118-5.239-4.879
10Y-42.292-5.743-36.549
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Impedimed is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 5.98 means the investor is paying $5.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Impedimed Ltd:

  • The EOD is 2.858. Based on the equity, the company is underpriced. +1
  • The MRQ is 5.982. Based on the equity, the company is overpriced. -1
  • The TTM is 5.982. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.858MRQ5.982-3.124
MRQ5.982TTM5.9820.000
TTM5.982YOY2.418+3.564
TTM5.9825Y7.075-1.092
5Y7.07510Y17.637-10.563
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD2.8582.151+0.707
MRQ5.9822.382+3.600
TTM5.9822.554+3.428
YOY2.4183.284-0.866
5Y7.0753.863+3.212
10Y17.6374.231+13.406
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Impedimed Ltd.

3.1. Funds holding Impedimed Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-01-31DFA Asia Pacific Small Company Series0.029999999-417437--
Total 0.029999999041743700.0%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Impedimed Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0050.0050%0.013-61%0.002+98%0.002+96%
Book Value Per Share--0.0300.0300%0.025+19%0.018+69%0.020+49%
Current Ratio--8.8848.8840%6.443+38%5.202+71%8.207+8%
Debt To Asset Ratio--0.1140.1140%0.130-12%0.194-41%0.143-20%
Debt To Equity Ratio--0.1290.1290%0.150-14%0.252-49%0.177-27%
Dividend Per Share--0.0000.0000%0.000+14%0.000+19%0.000+137%
Eps---0.010-0.0100%-0.010-3%-0.011+4%-0.010+2%
Free Cash Flow Per Share---0.012-0.0120%-0.010-13%-0.010-14%-0.010-19%
Free Cash Flow To Equity Per Share--0.0020.0020%0.009-80%0.001+79%0.002+14%
Gross Profit Margin--1.0221.0220%1.034-1%1.030-1%1.041-2%
Intrinsic Value_10Y_max---0.080--------
Intrinsic Value_10Y_min---0.105--------
Intrinsic Value_1Y_max---0.009--------
Intrinsic Value_1Y_min---0.010--------
Intrinsic Value_3Y_max---0.027--------
Intrinsic Value_3Y_min---0.032--------
Intrinsic Value_5Y_max---0.043--------
Intrinsic Value_5Y_min---0.053--------
Market Cap174004655.872-109%364195791.360364195791.3600%123421907.072+195%209493512.430+74%710970884.033-49%
Net Profit Margin---1.824-1.8240%-1.894+4%-3.161+73%-3.605+98%
Operating Margin---2.044-2.0440%-2.052+0%-3.588+76%-3.829+87%
Operating Ratio--3.0443.0440%3.0520%4.588-34%4.958-39%
Pb Ratio2.858-109%5.9825.9820%2.418+147%7.075-15%17.637-66%
Pe Ratio-8.479+52%-17.747-17.7470%-6.210-65%-9.857-44%-35.691+101%
Price Per Share0.086-109%0.1800.1800%0.061+195%0.104+74%0.351-49%
Price To Free Cash Flow Ratio-7.223+52%-15.117-15.1170%-5.910-61%-10.118-33%-42.292+180%
Price To Total Gains Ratio16.960-109%35.49735.4970%4.765+645%-25.586+172%1.641+2063%
Quick Ratio--8.4768.4760%6.096+39%4.850+75%7.735+10%
Return On Assets---0.299-0.2990%-0.339+13%-0.590+98%-0.524+75%
Return On Equity---0.337-0.3370%-0.389+16%-0.768+128%-0.638+89%
Total Gains Per Share--0.0050.0050%0.013-60%0.003+92%0.003+97%
Usd Book Value--39954887.70039954887.7000%33500177.200+19%23703324.580+69%26842998.150+49%
Usd Book Value Change Per Share--0.0030.0030%0.008-61%0.002+98%0.002+96%
Usd Book Value Per Share--0.0200.0200%0.017+19%0.012+69%0.013+49%
Usd Dividend Per Share--0.0000.0000%0.000+14%0.000+19%0.000+137%
Usd Eps---0.007-0.0070%-0.006-3%-0.007+4%-0.007+2%
Usd Free Cash Flow---15811579.600-15811579.6000%-13706825.500-13%-13635682.580-14%-12780654.940-19%
Usd Free Cash Flow Per Share---0.008-0.0080%-0.007-13%-0.007-14%-0.006-19%
Usd Free Cash Flow To Equity Per Share--0.0010.0010%0.006-80%0.001+79%0.001+14%
Usd Market Cap114199255.649-109%239021697.870239021697.8700%81001797.611+195%137490592.208+74%466610191.191-49%
Usd Price Per Share0.056-109%0.1180.1180%0.040+195%0.068+74%0.231-49%
Usd Profit---13467932.300-13467932.3000%-13043306.200-3%-13975777.240+4%-13777771.530+2%
Usd Revenue--7382718.7007382718.7000%6887868.500+7%5235830.140+41%4240223.040+74%
Usd Total Gains Per Share--0.0030.0030%0.008-60%0.002+92%0.002+97%
 EOD+2 -6MRQTTM+0 -0YOY+21 -155Y+31 -510Y+27 -9

4.2. Fundamental Score

Let's check the fundamental score of Impedimed Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.479
Price to Book Ratio (EOD)Between0-12.858
Net Profit Margin (MRQ)Greater than0-1.824
Operating Margin (MRQ)Greater than0-2.044
Quick Ratio (MRQ)Greater than18.476
Current Ratio (MRQ)Greater than18.884
Debt to Asset Ratio (MRQ)Less than10.114
Debt to Equity Ratio (MRQ)Less than10.129
Return on Equity (MRQ)Greater than0.15-0.337
Return on Assets (MRQ)Greater than0.05-0.299
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Impedimed Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.931
Ma 20Greater thanMa 500.092
Ma 50Greater thanMa 1000.122
Ma 100Greater thanMa 2000.129
OpenGreater thanClose0.087
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets68,736
Total Liabilities7,857
Total Stockholder Equity60,879
 As reported
Total Liabilities 7,857
Total Stockholder Equity+ 60,879
Total Assets = 68,736

Assets

Total Assets68,736
Total Current Assets51,935
Long-term Assets16,801
Total Current Assets
Cash And Cash Equivalents 45,710
Net Receivables 3,843
Inventory 810
Other Current Assets 541
Total Current Assets  (as reported)51,935
Total Current Assets  (calculated)50,904
+/- 1,031
Long-term Assets
Property Plant Equipment 1,951
Goodwill 2,730
Long Term Investments 78
Intangible Assets 12,042
Long-term Assets  (as reported)16,801
Long-term Assets  (calculated)16,801
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,846
Long-term Liabilities2,011
Total Stockholder Equity60,879
Total Current Liabilities
Short-term Debt 300
Accounts payable 1,355
Other Current Liabilities 1,031
Total Current Liabilities  (as reported)5,846
Total Current Liabilities  (calculated)2,686
+/- 3,160
Long-term Liabilities
Long term Debt Total 1,147
Other Liabilities 864
Long-term Liabilities  (as reported)2,011
Long-term Liabilities  (calculated)2,011
+/-0
Total Stockholder Equity
Common Stock336,087
Retained Earnings -311,162
Accumulated Other Comprehensive Income 35,954
Total Stockholder Equity (as reported)60,879
Total Stockholder Equity (calculated)60,879
+/-0
Other
Capital Stock336,087
Cash And Equivalents13,548
Cash and Short Term Investments 45,710
Common Stock Shares Outstanding 1,800,349
Current Deferred Revenue3,160
Liabilities and Stockholders Equity 68,736
Net Debt -44,263
Net Invested Capital 60,879
Net Tangible Assets 46,107
Net Working Capital 46,089
Property Plant and Equipment Gross 5,617
Short Long Term Debt Total 1,447



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
> Total Assets 
4,630
21,789
14,515
13,098
24,910
22,805
19,614
11,864
14,958
37,917
90,570
64,343
41,767
22,581
33,064
34,205
58,699
68,736
68,73658,69934,20533,06422,58141,76764,34390,57037,91714,95811,86419,61422,80524,91013,09814,51521,7894,630
   > Total Current Assets 
0
18,556
10,751
8,479
21,194
20,214
17,267
9,433
12,740
35,118
87,649
61,255
37,800
16,973
25,450
25,650
46,660
51,935
51,93546,66025,65025,45016,97337,80061,25587,64935,11812,7409,43317,26720,21421,1948,47910,75118,5560
       Cash And Cash Equivalents 
0
16,266
8,485
6,634
18,789
17,930
14,545
7,316
10,812
32,582
82,254
54,884
31,345
11,330
19,663
19,681
40,730
45,710
45,71040,73019,68119,66311,33031,34554,88482,25432,58210,8127,31614,54517,93018,7896,6348,48516,2660
       Short-term Investments 
0
148
31
0
0
31
31
0
0
0
0
0
0
0
0
0
0
0
00000000000313100311480
       Net Receivables 
786
979
866
744
773
673
769
449
445
633
3,507
3,804
4,306
3,488
3,730
3,705
3,414
3,843
3,8433,4143,7053,7303,4884,3063,8043,507633445449769673773744866979786
       Other Current Assets 
405
329
163
152
257
334
297
338
351
265
510
1,102
338
497
785
895
967
541
5419678957854973381,102510265351338297334257152163329405
   > Long-term Assets 
0
3,233
3,764
4,619
3,716
2,591
2,347
2,431
2,218
2,799
2,921
3,088
3,967
5,608
7,614
8,555
12,039
16,801
16,80112,0398,5557,6145,6083,9673,0882,9212,7992,2182,4312,3472,5913,7164,6193,7643,2330
       Property Plant Equipment 
169
248
396
665
539
425
404
334
203
298
396
518
368
188
1,015
1,030
418
1,951
1,9514181,0301,015188368518396298203334404425539665396248169
       Goodwill 
1,897
0
2,040
2,252
2,117
1,711
1,784
1,985
1,924
2,368
2,436
2,358
2,449
2,584
2,636
2,415
2,630
2,730
2,7302,6302,4152,6362,5842,4492,3582,4362,3681,9241,9851,7841,7112,1172,2522,04001,897
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
48
158
95
45
77
73
75
78
787573774595158480000000000
       Intangible Assets 
2,391
2,891
1,286
1,550
920
367
68
49
41
40
41
54
1,055
2,791
3,886
5,037
8,736
12,042
12,0428,7365,0373,8862,7911,0555441404149683679201,5501,2862,8912,391
       Long-term Assets Other 
0
94
0
124
0
0
0
0
0
31
0
0
3,967
5,608
-7,614
-8,555
180
-16,801
-16,801180-8,555-7,6145,6083,9670031000001240940
> Total Liabilities 
9,309
2,385
2,215
3,031
2,680
2,122
2,304
1,270
1,426
3,080
5,316
5,546
5,765
6,796
5,703
8,691
7,655
7,857
7,8577,6558,6915,7036,7965,7655,5465,3163,0801,4261,2702,3042,1222,6803,0312,2152,3859,309
   > Total Current Liabilities 
9,125
2,272
1,869
2,595
2,529
1,975
2,206
1,186
1,336
2,976
5,201
5,469
5,663
6,661
5,109
8,134
7,242
5,846
5,8467,2428,1345,1096,6615,6635,4695,2012,9761,3361,1862,2061,9752,5292,5951,8692,2729,125
       Short-term Debt 
0
711
64
0
0
0
0
0
0
0
0
0
0
364
364
315
170
300
3001703153643640000000000647110
       Accounts payable 
753
979
723
962
790
744
1,034
303
350
1,131
1,828
2,142
2,516
2,086
1,913
1,296
2,638
1,355
1,3552,6381,2961,9132,0862,5162,1421,8281,1313503031,034744790962723979753
       Other Current Liabilities 
7,318
322
1,082
1,633
1,739
1,231
1,172
883
986
1,845
3,373
3,327
3,147
4,575
578
877
928
1,031
1,0319288775784,5753,1473,3273,3731,8459868831,1721,2311,7391,6331,0823227,318
   > Long-term Liabilities 
0
113
346
436
151
147
98
84
90
104
115
77
102
135
594
557
413
2,011
2,011413557594135102771151049084981471514363461130
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
507
159
0
1,147
1,147015950700000000000000
       Capital Lease Obligations Min Short Term Debt
0
-711
-64
0
0
0
0
0
0
0
0
0
0
-364
507
159
0
1,147
1,1470159507-3640000000000-64-7110
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
218
360
422
422360218000000000000000
> Total Stockholder Equity
0
19,404
12,300
10,067
22,230
20,683
17,310
10,594
13,532
34,837
85,254
58,797
36,002
15,785
27,361
25,514
51,044
60,879
60,87951,04425,51427,36115,78536,00258,79785,25434,83713,53210,59417,31020,68322,23010,06712,30019,4040
   Retained Earnings -311,162-290,641-270,767-250,061-228,717-204,396-177,222-149,651-123,671-108,874-100,939-92,475-80,133-65,311-53,909-39,881-31,8090
   Accumulated Other Comprehensive Income 
0
1,187
1,372
2,491
2,982
2,812
3,683
5,432
5,813
11,159
16,098
16,526
20,652
24,775
26,859
29,013
34,127
35,954
35,95434,12729,01326,85924,77520,65216,52616,09811,1595,8135,4323,6832,8122,9822,4911,3721,1870
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.